title: Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer.
abstract: OBJECTIVE
  Five European centres (France, Finland, Italy, Spain and the UK) have pooled data to generate a large patient series involving 1175 patients treated with prostate brachytherapy. This paper reports preliminary data on PSA outcome up to 4 years.
  
  
  METHODS
  Out of 1175 in the database, 1050 patients with localised prostate cancer who had received transperineal seed implantation as monotherapy between May 1998 and August 2003 were stage T1-T2. A total of 668 (63.6%) patients met the low-risk group definition, 297 (28.3%) as intermediate-risk definition and 66 (6.3%) the high-risk group definition. The majority of patients were Gleason score 6 or less (n=951) and disease stage was T1c in 557 patients.
  
  
  RESULTS
  Of the 1050 patients, PSA data up to 4 years were available for 210 patients, while 364 patients with PSA values up to 36 months were evaluable by the Kaplan-Meier method for freedom from biochemical failure. The biochemical progression-free rate at 3 years was estimated to be 91%, with a 93% and 88% rate for low- and intermediate-risk groups, respectively, versus 80% for the high-risk group. PSA kinetics provide encouraging evidence of treatment efficacy.
  
  
  CONCLUSIONS
  These data on 4-year PSA follow-up on patients treated with prostate brachytherapy reflect those previously reported in the literature. This patient series will be followed to provide long-term outcome in the future.
authors.affiliation: Department of Radiotherapy, Catalan Institute of Oncology, Barcelona, Spain. guedea@ico.scs.es
authors.forename: Ferran
authors.initials: F
authors.lastname: Guedea
authors.forename: Ferran
authors.initials: F
authors.lastname: Aguilo
authors.forename: Alfredo
authors.initials: A
authors.lastname: Polo
authors.forename: Stephen
authors.initials: S
authors.lastname: Langley
authors.forename: Robert
authors.initials: R
authors.lastname: Laing
authors.forename: Alastair
authors.initials: A
authors.lastname: Henderson
authors.forename: Sirpa
authors.initials: S
authors.lastname: Aaltomaa
authors.forename: Vesa
authors.initials: V
authors.lastname: Kataja
authors.forename: Juni
authors.initials: J
authors.lastname: Palmgren
authors.forename: Franch
authors.initials: F
authors.lastname: Bladou
authors.forename: Naji
authors.initials: N
authors.lastname: Salem
authors.forename: Gwenaelle
authors.initials: G
authors.lastname: Gravis
authors.forename: Andrea
authors.initials: A
authors.lastname: Losa
authors.forename: Giorgio
authors.initials: G
authors.lastname: Guazzoni
authors.forename: Luciano
authors.initials: L
authors.lastname: Nava
mesh_terms: D000368:Aged; D001918:Brachytherapy / Q000379:methods*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000096:biosynthesis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000532:radiotherapy*; D011874:Radiometry; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen